Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
JCSM Rapid Commun ; 5(1): 52-67, 2022.
Article in English | MEDLINE | ID: mdl-36118249

ABSTRACT

Background: Low muscle in cancer is associated with an increase in treatment-related toxicities and is a predictor of cancer-related and all-cause mortality. The mechanisms of cancer-related muscle loss are multifactorial, including anorexia, hypogonadism, anaemia, inflammation, malnutrition, and aberrations in skeletal muscle protein turnover and metabolism. Methods: In this narrative review, we summarise relevant literature to (i) review the factors influencing skeletal muscle mass regulation, (ii) provide an overview of how cancer/treatments negatively impact these, (iii) review factors beyond muscle signalling that can impact the ability to participate in and respond to an exercise intervention to counteract muscle loss in cancer, and (iv) provide perspectives on critical areas of future research. Results: Despite the well-known benefits of exercise, there remains a paucity of clinical evidence supporting the impact of exercise in cancer-related muscle loss. There are numerous challenges to reversing muscle loss with exercise in clinical cancer settings, ranging from the impact of cancer/treatments on the molecular regulation of muscle mass, to clinical challenges in responsiveness to an exercise intervention. For example, tumour-related/treatment-related factors (e.g. nausea, pain, anaemia, and neutropenia), presence of comorbidities (e.g. diabetes, arthritis, and chronic obstructive pulmonary disease), injuries, disease progression and bone metastases, concomitant medications (e.g., metformin), can negatively affect an individual's ability to exercise safely and limit subsequent adaptation. Conclusions: This review identifies numerous gaps and oppportunities in the area of low muscle and muscle loss in cancer. Collaborative efforts between preclinical and clinical researchers are imperative to both understanding the mechanisms of atrophy, and develop appropriate therapeutic interventions.

2.
Beilstein J Nanotechnol ; 12: 282-294, 2021.
Article in English | MEDLINE | ID: mdl-33842185

ABSTRACT

Silver nanoparticles (AgNPs) are widely used in medical applications due to their antibacterial and antiviral properties. Despite the extensive study of AgNPs, their toxicity and their effect on human health is poorly understood, as a result of issues such as poor control of NP properties and lack of proper characterization. The aim of this study was to investigate the combined characterization, bio-uptake, and toxicity of well-characterized polyvinylpyrrolidone (PVP)-coated AgNPs in exposure media during exposure time using primary human cells (peripheral blood mononuclear cells (PBMCs)). AgNPs were synthesized in-house and characterized using a multimethod approach. Results indicated the transformation of NPs in RPMI medium with a change in size and polydispersity over 24 h of exposure due to dissolution and reprecipitation. No aggregation of NPs was observed in the RPMI medium over the exposure time (24 h). A dose-dependent relationship between PBMC uptake and Ag concentration was detected for both AgNP and AgNO3 treatment. There was approximately a two-fold increase in cellular Ag uptake in the AgNO3 vs the NP treatment. Cytotoxicity, using LDH and MTS assays and based on exposure concentrations was not significantly different when comparing NPs and Ag ions. Based on differential uptake, AgNPs were more toxic after normalizing toxicity to the amount of cellular Ag uptake. Our data highlights the importance of correct synthesis, characterization, and study of transformations to obtain a better understanding of NP uptake and toxicity. Statistical analysis indicated that there might be an individual variability in response to NPs, although more research is required.

3.
Women Health ; 60(7): 792-805, 2020 08.
Article in English | MEDLINE | ID: mdl-32248760

ABSTRACT

Lifestyle interventions may reduce inflammation and lower breast cancer (BrCa) risk. This randomized trial assessed the impact of the Sistas Inspiring Sistas Through Activity and Support (SISTAS) study on plasma C-reactive protein (CRP), interleukin-6 (IL-6) and Dietary Inflammatory Index (DII). This unblinded, dietary and physical activity trial was implemented in 337 obese (body mass index [BMI] ≥30 kg/m2) African American (AA) women recruited between 2011 and 2015 in South Carolina through a community-based participatory approach with measurements at baseline, 3 months, and 12 months. Participants were randomized into either intervention (n = 176) or wait-list control group (n = 161). Linear mixed-effect models were used for analyses of CRP and IL-6. Baseline CRP was significantly higher in those with greater obesity, body fat percentage, and waist circumference (all p <.01). No difference was observed between groups for CRP or IL-6 at 3 or 12 months; however, improvements in diet were observed in the intervention group compared to the control group (p = .02) at 3 months but were not sustained at 12 months. Although the intervention was not successful at reducing levels of CRP or IL-6, a significant decrease was observed in DII score for the intervention group, indicating short-term positive dietary change.


Subject(s)
Black or African American/statistics & numerical data , C-Reactive Protein/analysis , C-Reactive Protein/metabolism , Diet , Exercise , Inflammation/diet therapy , Inflammation/etiology , Interleukin-6/blood , Adult , Aged , Biomarkers/blood , Community-Based Participatory Research , Female , Humans , Inflammation/blood , Life Style , Middle Aged , Obesity/diet therapy , Obesity/therapy , Socioeconomic Factors , South Carolina , Treatment Outcome
4.
Oncotarget ; 9(25): 17928-17936, 2018 Apr 03.
Article in English | MEDLINE | ID: mdl-29707158

ABSTRACT

Chemokines (CXCR3) and their ligands (CXCL9, CXCL10, and CXCL11) exert exquisite control over T-cell trafficking and are critical for activation, differentiation and effector T cell function. CXCR3 is important for CD4 Th1 cells, CD8 effectors, memory cells, and for the function of natural killer and natural killer T cells. The presence of high cytotoxic CXCR3 ligand expression on CD8 T cells in colorectal cancerous tissue has been well documented in the past. CXCR3 and its ligands are differentially expressed at sites of inflammation and within the tumors. Further, the expression of CXCR3 and its ligands has been correlated with both the presence of effector T cells within tumor tissue and disease-free survival of patients. However, effector T cell infiltration into primary and metastatic tumors is highly variable and, in fact, often absent. Thus, understanding why T cells fail to infiltrate into tumors and determining the way to improve effector T cell entry into tumors would be important advances in efforts to harness the power of the immune system to fight cancer. To this end, the recent exciting discovery that CXCR3 is functionally expressed on regulatory T cells and also induces the differentiation of peripheral CD4 T cells into regulatory T cells, might address the novel clinically relevant question of the therapeutic potential of the CXCR3 system. This is also coupled with the fact that increases in CXCR3 expression also improves effector T cell function. This review describes the differential role of CXCR3 induction on peripheral and tumor microenvironment inflammation. Further, this review, tied with important findings from our laboratory, demonstrates that polyphenols induce CXCR3 expression on regulatory T cells and increases CXCR3 ligands in the tumor microenvironment, which act together to suppress colorectal cancer through a differential mechanism discussed herewith.

5.
Immunology ; 143(3): 478-89, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24891206

ABSTRACT

Inflammatory bowel disease (IBD), a chronic intestinal inflammatory condition that affects millions of people worldwide, results in high morbidity and exorbitant health-care costs. The critical features of both innate and adaptive immunity are to control inflammation and dysfunction in this equilibrium is believed to be the reason for the development of IBD. miR-155, a microRNA, is up-regulated in various inflammatory disease states, including IBD, and is a positive regulator of T-cell responses. To date, no reports have defined a function for miR-155 with regard to cellular responses in IBD. Using an acute experimental colitis model, we found that miR-155(-/-) mice, as compared to wild-type control mice, have decreased clinical scores, a reversal of colitis-associated pathogenesis, and reduced systemic and mucosal inflammatory cytokines. The increased frequency of CD4+ lymphocytes in the spleen and lamina propria with dextran sodium sulphate induction was decreased in miR-155(-/-) mice. Similarly, miR-155 deficiency abrogated the increased numbers of interferon-γ expressing CD4+ T cells typically observed in wild-type mice in this model. The frequency of systemic and mucosal T helper type 17-, CCR9-expressing CD4+ T cells was also reduced in miR-155(-/-) mice compared with control mice. These findings strongly support a role for miR-155 in facilitating pro-inflammatory cellular responses in this model of IBD. Loss of miR-155 also results in decreases in T helper type 1/type 17, CD11b+) and CD11c+ cells, which correlated with reduced clinical scores and severity of disease. miR-155 may serve as a potential therapeutic target for the treatment of IBD.


Subject(s)
Colitis/genetics , Colitis/immunology , MicroRNAs/genetics , Th1 Cells/immunology , Th1 Cells/metabolism , Th17 Cells/immunology , Th17 Cells/metabolism , Animals , Body Weight , CD11b Antigen/metabolism , CD11c Antigen/metabolism , Colitis/blood , Colitis/chemically induced , Colitis/pathology , Cytokines/blood , Dextran Sulfate/adverse effects , Disease Models, Animal , Female , Immunophenotyping , Lymphocyte Count , Mice , Mice, Knockout , Severity of Illness Index
6.
Integr Zool ; 6(1): 13-27, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21392359

ABSTRACT

Parasitic isopods (family Bopyridae) and burrowing barnacles (family Trypetesidae) infesting hermit crabs were investigated from shallow subtidal collections made along the southeastern coast of Spain in 2009. A total of 713 specimens of Clibanarius erythropus (Latreille, 1818) and 82 Calcinus tubularis (L., 1767) were examined. Gastropod shells and worm tubes inhabited by hermit crabs were collected by hand while snorkeling and were cracked to determine host species, size, sex and presence of eggs. Two species of bopyrid isopods were found on C. erythropus: the branchial parasite Bopyrissa fraiseii (Carayon, 1943) and the abdominal parasite Parathelges cardonae Codreanu and Codreanu in Codreanu, 1968. Among all C. erythropus examined, Bopyrissa fraiseii was found on 0.6% of hermit crabs and P. cardonae was found on 0.3%. A redescription of P. cardonae is provided and the species is documented with light and scanning electron microscopy for the first time. No Calcinus tubularis harbored parasitic isopods, but one specimen was parasitized by an unidentified rhizocephalan barnacle of the genus Septosaccus (1.2%). The burrowing barnacle Trypetesa lampas (Hancock, 1849) was found associated with both hermit crab species and evidence of predation on host eggs by this barnacle is shown for the first time. Trypetesa lampas was found in 4.2% of the shells collected. The present study expands our knowledge of the parasite fauna of hermit crabs from the Mediterranean Sea and indicates that additional research is needed to determine the impact of trypetesid egg predators on hermit crab populations.


Subject(s)
Anomura/parasitology , Isopoda/physiology , Predatory Behavior/physiology , Thoracica/physiology , Animals , Isopoda/anatomy & histology , Mediterranean Sea , Microscopy, Electron, Scanning , Ovum , Spain , Species Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...